Life Sciences

  • May 11, 2026

    Amgen Late To Raise Double-Taxation Claim, Tax Court Told

    Biotechnology giant Amgen is making a "futile" attempt to raise a purported double-taxation issue for tax years 2016 through 2018 in a pair of transfer pricing cases before the U.S. Tax Court, the federal government said, arguing the disputed years fall outside the court's jurisdiction.

  • May 11, 2026

    Trading Scheme Is A 'Wake-Up Call' For BigLaw Compliance

    The breadth of a decade-long insider trading scheme prosecutors say was fueled by stolen BigLaw merger information should jolt firms to reexamine their practices to close gaps in internal security, experts told Law360, even if totally eliminating bad actors is nearly impossible.

  • May 11, 2026

    Justices Extend Stay On 5th Circ. Mifepristone Decision

    The U.S. Supreme Court on Monday extended a stay that preserved, for now, telehealth access to the abortion medication mifepristone.

  • May 11, 2026

    Fed. Circ. Backs Atty Fee Ruling In Bone Fusion Patent Row

    The Federal Circuit on Monday backed a lower court that awarded $52,573 in attorney fees for Nextremity Solutions Inc.'s defense against a bone fusion patent suit and shot down Nextremity's bid for $343,660 in fees incurred at the Patent Trial and Appeal Board.

  • May 11, 2026

    Plaintiffs' Attys Sanctioned In Tylenol MDL, Sparking Appeal

    A New York federal court sanctioned a plaintiffs' firm and its co-founder in federal multidistrict litigation by families alleging that prenatal exposure to acetaminophen can cause autism, saying they improperly shared confidential information from the case in related state court actions.

  • May 08, 2026

    Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition

    A former U.S. Food and Drug Administration commissioner told an attorney for Johnson & Johnson she was "spinning" the definition of asbestos in an attempt to confuse a jury in a bellwether trial over claims the company's talc products caused three women's deaths from ovarian cancer.

  • May 08, 2026

    FTC's Gender-Care Probe Likely Retaliatory, Judge Says

    The Endocrine Society has convinced a D.C. federal judge that the Federal Trade Commission's motivation for targeting it with a subpoena was likely retaliation for the guidelines the nonprofit produced regarding gender-affirming care.

  • May 08, 2026

    10x, Curio Settle Genomics Patent Suit Before Trial

    10x Genomics on Friday said it has agreed to end its suit accusing Curio Bioscience of infringing a series of Prognosys Biosciences genomics technology patents that 10x Genomics is licensed to use.

  • May 08, 2026

    Sports Tech Co. Says Judge Made Own Patent Eligibility Case

    Finnish sports tech company Polar Electro has asked the U.S. Supreme Court to revive its infringement case against a rival over a heart monitoring patent, saying a district judge made up his own case for patent eligibility when he ruled the patent was invalid.

  • May 08, 2026

    10x, Harvard Sue Sequencing Co. Over Biology Patents

    10x Genomics Inc. and Harvard have sued Element Biosciences Inc. in Delaware federal court, accusing the San Diego sequencing company of infringing four Harvard-owned patents through Element's AVITI24 platform and related Teton chemistry.

  • May 08, 2026

    Ex-Wachtell Lipton Atty Tied To Stolen BigLaw Info Trades

    A former Wachtell Lipton Rosen & Katz attorney who later worked for investment bank LionTree LLC is an unindicted co-conspirator in a sweeping alleged insider trading scheme that involved stolen information from several prominent law firms, according to a review of publicly available information.

  • May 08, 2026

    Covington, Cooley Lead Drugmaker Odyssey's $279M IPO

    Venture-backed biotechnology firm Odyssey Therapeutics began trading publicly Friday after raising $279 million in its initial public offering, making it the latest biotech to hit the public markets over the last few weeks.

  • May 08, 2026

    Squires Says Yes To 7 Patent Petitions, No To A Dozen More

    U.S. Patent and Trademark Office Director John Squires granted seven petitions for patent review under the America Invents Act and denied 12 other petitions, including a host of challenges by Cisco Systems and Samsung Electronics.

  • May 08, 2026

    Don't Miss It: Paul Hastings, V&E Steer Latest Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple weeks, and it's difficult to keep up with all the deals.

  • May 08, 2026

    Catalent Agrees To Pay $78M To Settle Securities Suit

    Catalent Inc. agreed on Thursday to pay $78 million to settle a securities class action from a group of investors who alleged the vaccine manufacturer engaged in accounting and channel stuffing schemes and cut corners on safety to pad its revenues.

  • May 08, 2026

    Walgreens Loses Atty Sanctions Bid In Georgia Bias Suit

    The attorney for a former pharmacist suing Walgreens for discrimination has escaped a sanctions bid after a Georgia federal judge found the chain gave the lawyer too little time to respond to a motion to dismiss claims.

  • May 08, 2026

    Cardiac Device Co. Says Ex-Manager Took Secrets To Rival

    Vital Connect Inc., a company that sells wearable cardiac monitoring devices, told a North Carolina federal court that a former senior key accounts manager pilfered its confidential information only to decamp to a competitor and begin soliciting its clients.

  • May 08, 2026

    Squires Says Fitness Tracker Patent Date Key To PGR Ruling

    Wearable technology company Whoop Inc. has shown that an Omni Medsci Inc. patent can be challenged under the America Invents Act because its effective filing was after a cutoff date in the law, U.S. Patent and Trademark Office Director John Squires has found.

  • May 07, 2026

    Fed. Circ. Judges Stuck On Drug Efficacy's Role In Patents

    A Federal Circuit panel struggled Thursday to pin down where the line is between patent enablement on cancer drug patents and U.S. Food and Drug Administration standards, as a Pfizer unit tried to revive its $107 million jury victory over AstraZeneca.

  • May 07, 2026

    J&J Feared FDA's 'Disturbing Proposal' To Test Talc, Jury Told

    A former U.S. Food and Drug Administration commissioner testifying Thursday in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused three women's deadly ovarian cancer described an internal document showing J&J feared the FDA's "disturbing proposal" to test the talc instead of relying on industry self-testing.

  • May 07, 2026

    La. Says Mailed Abortion Pills Harm State Budget, Sovereignty

    The state of Louisiana on Thursday defended its standing to challenge telehealth access to the abortion medication mifepristone, telling the U.S. Supreme Court that it has suffered financial and other injuries as mail-order pills flood the state.

  • May 07, 2026

    Judge, In 'Difficult Position,' OKs Rare Patent Defense

    A Massachusetts federal judge found himself in what he said was a "difficult position" in allowing an unusual defense to be advanced in a patent infringement case related to blood pumps in light of criticism of the defense from the Federal Circuit.

  • May 07, 2026

    $495M Win Upheld In Abbott Baby Formula Bellwether Trial

    A Missouri appellate panel on Tuesday upheld a trial win of $95 million in compensatory damages and $400 million in punitive damages over bellwether claims that Abbott Laboratories' baby formula caused a premature baby to suffer a fully disabling condition.

  • May 07, 2026

    Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill

    Bayer AG has been hit with a proposed class action in New York federal court alleging that claims on its Men's One A Day Pre-Conception Health Multivitamin supplements misleadingly convey that they could improve chances of conception and support sperm health.

  • May 07, 2026

    Bayer Loses Bid To Undo Class In 'One A Day' Label Suit

    A New York federal judge on Wednesday declined to decertify a class action alleging that Bayer's "One A Day" gummy vitamins deceive consumers about serving sizes, allowing the case to continue since there's evidence that a significant number of consumers could be confused.

Expert Analysis

  • 5 Advertising Law Trends That Will Shape 2026

    Author Photo

    The legal landscape for advertisers will grow only more complex this year, with ongoing trends including a federal regulatory retreat, more aggressive action by the states, a focus on child privacy and expanded scrutiny of "natural" claims, say attorneys at Reed Smith.

  • Cannabis Industry Faces An Inflection Point This Year

    Author Photo

    Cannabis industry developments last year — from the passage of a new wholesale tax in Michigan, to an executive order accelerating the federal rescheduling process — presage a more mature phase of legalization this year, with hardening expectations and enforcement to come, says Alex Leonowicz at Howard & Howard.

  • Series

    Fly-Fishing Makes Me A Better Lawyer

    Author Photo

    Much like skilled attorneys, the best anglers prize preparation, presentation and patience while respecting their adversaries — both human and trout, says Rob Braverman at Braverman Greenspun.

  • 4 Ways GCs Can Manage Growing Service Of Process Volume

    Author Photo

    As automation and arbitration increase the volume of legal filings, in-house counsel must build scalable service of process systems that strengthen corporate governance and manage risk in real time, says Paul Mathews at Corporation Service Co.

  • Series

    The Law Firm Merger Diaries: Forming Measurable Ties

    Author Photo

    Relationship-building should begin as early as possible in a law firm merger, as intentional pathways to bringing people together drive collaboration, positive client response, engagements and growth, says Amie Colby at Troutman.

  • AG Watch: Va. Insulin Price Probe Signals Rising Scrutiny

    Author Photo

    Virginia Attorney General Jason Miyares' recent investigation into insulin manufacturers and pharmacy benefit managers for allegedly colluding to artificially inflate insulin prices reflects a broader trend to leverage consumer protection authority in high-impact healthcare matters, and the upcoming leadership change is unlikely to diminish scrutiny in this area, says Chuck Slemp at Cozen O'Connor.

  • FDA's AI Deployment Brings New Potential And Risks

    Author Photo

    The U.S. Food and Drug Administration's recent announcement about making agentic artificial intelligence tools available to agency employees may portend accelerated regulatory timelines and lower costs for drug companies and consumers, but potential errors and biases will necessitate additional safeguards, says Angela Silva at Lewis Brisbois.

  • 3 Key Takeaways From Planned Rescheduling Of Cannabis

    Author Photo

    An executive order reviving cannabis rescheduling represents a monumental change for the industry and, while the substance will remain illegal at the federal level, introduces several benefits, including improving state-legal cannabis operators' tax treatment, lowering the industry's legal risk profile, and leaving state-regulated markets largely intact, say attorneys at Dentons.

  • 6 Issues That May Follow The 340B Rebate Pilot Challenge

    Author Photo

    Though the Health Resources and Services Administration withdrew a pending case to reconsider the controversial 340B rebate pilot program, a number of crucial considerations remain, including the likelihood of a rework and questions about what that rework might look like, say attorneys at Spencer Fane.

  • 5 E-Discovery Predictions For 2026 And Beyond

    Author Photo

    2026 will likely be shaped by issues ranging from artificial intelligence regulatory turbulence to potential evidence rule changes, and e-discovery professionals will need to understand how to effectively guide the responsible and defensible adoption of emerging tools, while also ensuring effective safeguards, say attorneys at Littler.

  • Streamlining Product Liability MDLs With AI And Rule 16.1

    Author Photo

    With newly effective Rule 16.1 of the Federal Rules of Civil Procedure providing enhanced guidance on multidistrict litigation and the sophistication of artificial intelligence continuing to advance, parties have the opportunity to better confront the significant data challenges presented by product liability MDLs, say attorneys at Hollingsworth.

  • Business Considerations Amid Hemp Product Policy Change

    Author Photo

    With the passage of a bill fundamentally narrowing the federal definition of "hemp," there are practical and business considerations that brands, manufacturers and other parties should heed over the next year, including operational strategies, evaluating contract and counterparty risk, and tax implications, say attorneys at Foley Hoag.

  • Series

    Judges On AI: How Courts Can Boost Access To Justice

    Author Photo

    Arizona Court of Appeals Judge Samuel A. Thumma writes that generative artificial intelligence tools offer a profound opportunity to enhance access to justice and engender public confidence in courts’ use of technology, and judges can seize this opportunity in five key ways.

  • Fed. Circ. In November: Looking For Patent 'Blaze Marks'

    Author Photo

    The Federal Circuit's recent decision in Duke v. Sandoz serves as a warning that when patentees craft claims, they must provide adequate "blaze marks" that direct a skilled artisan to the specific claimed invention, and not just the individual claimed elements in isolation, say attorneys at Knobbe Martens.

  • 2025's Most Notable State AG Activity By The Numbers

    Author Photo

    State attorneys general were active in 2025, working across party lines to address federal regulatory gaps in artificial intelligence, take action on consumer protection issues, continue antitrust enforcement and announce large settlements on behalf of their citizens, say attorneys at Jenner & Block.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.